New York Medical College Announces First Incubator Tenants
“Our first three tenants demonstrate that the promise of the incubator is being fulfilled
Jennifer Riekert, M.B.A.
Vice President of Communications
New York Medical College
BioInc@NYMC is the only incubator of its kind in the region that is located on a medical school campus
Valhalla, N.Y. – January 15, 2015 – New York Medical College (NYMC) today announced the first three tenants of its recently launched biotechnology incubator, BioInc@NYMC in keeping with its mission to find new ways to prevent and treat human disease and disability, Conversion Energy Enterprises (CEE), a corporation that develops and prototypes laser products for medical applications; MB Group USA, a supplier of products derived from rare fruits for health purposes; and MOE Medical Devices, LLC, a maker of cold electrical plasma therapeutics applied and were selected to be the first occupants of BioInc@NYMC, which was officially launched on October 29, 2014.
BioInc@NYMC occupies a 10,000 square-foot wing of a 129,000 square-foot campus building. An initial build-out of 4,500 square feet with finished laboratories, offices and shared infrastructure is ready for immediate occupancy. Development of the remaining space is planned to proceed as the initial spaces are filled. Additional available space in the same building (50,000-60,000 square feet) is ideal for future growth of the incubator or related biomedical research activities.
“Our first three tenants demonstrate that the promise of the incubator is being fulfilled: BioInc@NYMC is simultaneously generating and disseminating new knowledge about biomedicine while serving as a job creation engine and a source for Westchester's economic development,” said Edward C. Halperin, M.D., M.A., chancellor and chief executive officer.
“We are delighted to welcome our first tenants to BioInc@NYMC. CEE, MB Group USA and MOE Medical Devices, will truly bring our facility to life. It is our hope that BioInc@NYMC tenants will take full advantage of the incubator’s state-of-the-art resources and the campus’s prime location, with its proximity to New York City and access to NYMC services. These companies have already achieved great success and we look forward to seeing them continue to flourish in their new home,” said Randi Schwartz, M.B.A., interim director of BioInc@NYMC and associate dean for academic administration.
CEE produces pre-clinical systems and tissue adhesives based on its exclusive laser technology and light activated bio-adhesives. The company continues to commercialize its technology and introduce new products into the marketplace, providing innovative healing applications that are reliable and effective. In the near future, CEE hopes to expand facilities and staff to continue generating compelling products and data.
“Conversion Energy Enterprises is excited to be one of the first tenants at BioInc@NYMC,” said Barbara A. Soltz, CEO of CEE. “Working in an energetic, intellectually supportive environment that fosters innovation and development will help us to continue the work that we do and bring our company to the next level. We look forward to working alongside fellow entrepreneurs with similar goals and aspirations, and are grateful to New York Medical College for this opportunity.”
MB Group USA produces MiraBurst™ and MiraSweet™ products for chemotherapy cancer patients; diabetics seeking to regulate blood sugar; and health conscious people seeking to cut down on sugar, MiraBurst™ products temporarily alter the taste buds so that sour and acidic foods taste sweet and MiraSweet™ is an all-natural, zero calorie sugar substitute.
“We’re thrilled with the opportunity to leverage the intellectual collaboration at a medical school renown for ground-breaking medical and scientific advances. We look forward to continuing our work and clinical research in such an innovative environment as BioInc@NYMC,” said Emmanuel Assare, M.D., CEO of MiraBurst™.
MOE Medical Devices, LLC develops cold electrical plasma systems and therapeutics that have the potential to provide targeted destruction of pathogens and abnormal tissues while avoiding damage to surrounding, healthy tissue. MOE is currently running several clinical trials and pre-clinical studies with promising initial results for the treatment of onychomycosis – a fungal infection of the toenails or fingernails – and intraepithelial neoplasia, which are pre-cancerous lesions found in many areas of the body, including on the skin, gastrointestinal tract, reproductive organs, and oral cavity.
“MOE Medical Devices is thrilled to join the growing number of startups at the BioInc@NYMC and the larger New York Medical College community. Our vision is to build interdisciplinary collaborations among clinicians and engineers to enable creation of innovative energy-based therapeutics for difficult-to-treat conditions. We look forward to expanding our partnership and activities with the entire NYMC community.” said Marc Zemel, CEO of MOE Medical Devices.
A top regional economic priority in 2011, 2012 and 2013, BioInc@NYMC is a public-private enterprise, combining resources from the federal government, New York State, Westchester County and NYMC, and is the only incubator of its kind in the region that is directly co-located with a health science's university campus. BioInc@NYMC has been approved by Start-Up NY and has received the multi-year Mid-Hudson Innovation Hot Spot award granted by the New York State Regional Economic Development Council (REDC).
About New York Medical College
Founded in 1860, NYMC is one of the oldest and largest health sciences universities in the country with more than 1,400 students, 1,300 residents and clinical fellows, nearly 3,000 faculty members, and 15,000 living alumni. The College, which joined the Touro College and University System in 2011, is located in Westchester County, New York, and offers advanced degrees from the School of Medicine, the Graduate School of Basic Medical Sciences, and the School of Health Sciences and Practice. The College manages more than $36 million in research and other sponsored programs, notably in the areas of cancer, cardiovascular disease, infectious diseases, kidney disease, the neurosciences, disaster medicine, and vaccine development.
With a network of affiliated hospitals that includes large urban medical centers, small suburban clinics and high-tech regional tertiary care facilities, NYMC provides a wide variety of clinical training opportunities throughout the tri-state region for medical students, residents, and other health providers.